Does Medicare cover GLP-1 medications?

medicare

Reviewed by the WeighedHealth Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.

Content current as of July 2026; updated when guidance or availability changes.

Medicare is the federal health insurance program for adults 65+ and certain younger people with disabilities.

What Medicare specifically requires

Medicare GLP-1 Bridge: $50 per month for Wegovy (injection or tablet), Zepbound KwikPen or Foundayo, from July 1, 2026 through December 31, 2027. Zepbound single-dose pens and vials are not covered. Medicare.gov fact sheet 12234: Medicare GLP-1 Bridge, Jun 2026
Bridge eligibility: age 18 or older and BMI 35 or more; or BMI 30 or more with HFpEF, uncontrolled high blood pressure or chronic kidney disease stage 3a or higher; or BMI 27 or more with prediabetes, a prior heart attack, stroke or peripheral artery disease. Medicare.gov fact sheet 12234: Medicare GLP-1 Bridge, Jun 2026
The $50 Bridge copay does not count toward the Part D deductible or the yearly out-of-pocket limit. Medicare.gov fact sheet 12234: Medicare GLP-1 Bridge, Jun 2026
People with type 2 diabetes, moderate-to-severe sleep apnea or noncirrhotic MASH get GLP-1s through their Part D plan, not the Bridge. CMS: Medicare GLP-1 Bridge information for providers, Aug 6, 2026
Federal law lets drug plans exclude agents used for weight loss, hair growth, or erectile dysfunction (42 U.S.C. 1396r-8(d)(2)). 42 U.S.C. 1396r-8(d)(2): drugs that may be excluded or restricted, Current code

Medicare coverage by drug

Reminder: coverage varies by plan

Medicare offers many plan designs. The same medication can be covered under one Medicare plan and excluded from another. Always confirm with your specific plan's formulary or call the number on your insurance card before assuming coverage.

Frequently asked

Does Medicare cover GLP-1 medications for weight loss?+

Medicare Part D does not cover drugs used only for weight loss; federal law allows that exclusion. Part D covers GLP-1s for type 2 diabetes and for other FDA-approved uses such as sleep apnea (Zepbound) and MASH (Wegovy). From July 1, 2026 to December 31, 2027, the Medicare GLP-1 Bridge lets eligible Part D enrollees get Wegovy, Zepbound KwikPen or Foundayo for weight loss at $50 a month. GLP-1 coverage at Medicare varies plan by plan. For Wegovy and Zepbound (weight-loss indications), expect prior authorization at minimum, with formal documentation of BMI and previous lifestyle interventions. For Ozempic and Mounjaro (type 2 diabetes), coverage is generally easier when prescribed for diabetes.

Does Medicare require a prior authorization for Wegovy or Zepbound?+

Yes, prior authorization (PA) is the norm for weight-loss GLP-1s across Medicare plans. A PA typically requires documented BMI ≥30 (or ≥27 with a comorbidity), prior attempts at structured weight loss, and sometimes step-therapy through cheaper alternatives. Your prescriber's office files the PA.

How do I check if my specific Medicare plan covers a drug?+

Three steps: (1) Log into your Medicare member portal and search the drug formulary by name. (2) Call the member services number on your insurance card. (3) Ask your prescriber to submit a benefits inquiry. Plan designs differ widely within Medicare — what's covered for one member may not be covered for another.

What if Medicare denies my GLP-1 prior authorization?+

Three options: (1) Appeal — most plans grant an appeal that adds physician peer-to-peer review; your prescriber can request this. (2) Switch indication if clinically appropriate (e.g., if you have prediabetes and BMI ≥30, your physician may have different coverage paths). (3) Use manufacturer direct-pay (NovoCare, LillyDirect) which doesn't depend on insurance approval. Federal program coverage policies follow CMS rules and have less plan-by-plan variability — appeals are still available.

Are compounded GLP-1s covered by Medicare?+

Generally no. Most insurance plans, including Medicare, do not cover compounded semaglutide or tirzepatide regardless of pharmacy. As of 2026, the FDA is winding down large-scale compounding, so coverage questions are increasingly moot — most patients are transitioning to branded GLP-1s or manufacturer direct-pay programs.